Juno Therapeutics (JUNO) Advances; Filing Provides Update on License Agreement with Opus Bio
Tweet Send to a Friend
Juno Therapeutics (NASDAQ: JUNO) advanced Monday, gaining about 6% pre-market after filing an 8-K with the SEC. The 8-K noted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
